Medical cannabinoids deserve better.

At Folium Europe and FeyeCon, we’ve been working with cannabinoids since 2002, long before the wave of legalization began. What started as a movement to unlock the therapeutic potential of cannabis is now increasingly overshadowed by an opportunistic industry, where flowers are washed, and money is laundered.

Legal frameworks shift constantly. In theory, this creates space for medical innovation. In practice, we see a flood of low-grade flower products marketed under the label of “medical use.” Meanwhile, pharmaceutical formats, such as tinctures, salves, and controlled-dose drops, are sidelined or obstructed by monopolies and inconsistent policy.

Countries like Italy are reversing parts of their cannabis liberalization. Portugal is dealing with the unintended consequences of its open policy. Germany is moving ahead with adult-use reforms while keeping medical cannabis in focus. In the Netherlands, where a legal distinction between medical and recreational exists, a state-backed monopoly blocks progress in the medical sector.
The result? A market driven by recreational demand, where serious medical development risks being drowned out, or exploited by those uninterested in science, safety, or patients.

We believe cannabinoids have a rightful place in evidence-based medicine, and we do not advocate banning recreational use. Instead, these two domains must coexist, in a regulated, symbiotic system that separates fact from sentiment.
That requires: regulatory clarity and market protection against market opportunism both in medical and recreational.

It is like catching smoke, but the conversation needs to shift, again.

#Cannabinoids #MedicalCannabis #PharmaInnovation #Regulation #Sustainability #FeyeCon #FoliumEurope

This website uses cookies to ensure you get the best experience on our website. Learn More